Skip to main content
. 2023 Jan 1;13(2):767–786. doi: 10.7150/thno.79806

Table 2.

Summary of described immune effects by RPT.

Classification Description Model (tumor cell line or indication) Radionuclide Ref
DAMP Calreticulin, HSP70, HSP90, and HMGB1 ↑ Cells (MC38, MDA-MB-231, ZR75-1, LNCaP, PC3, H1703, H441, OVCAR-3) 223Ra 227Th 213Bi 66, 72, 76
Tumor surface Fas, ICAM-1 ↑ Cells (MC38-CEA+)/Mouse (B78) 153Sm 90Y 81, 84
MHC-I ↑ Cells (MC38, MDA-MB-231, ZR75-1, LNCaP, PC3, H1703, H441, OVCAR-3) 233Ra 153Sm 72, 91
Other TAAs (PSA, CEA and MUC-1) ↑ Cells (LNCaP) 153Sm 91
PD-L1 ↑ Cells/Mouse (MC38, CT26) 18F 64Cu 97, 99
T cells T cells are essential for the antitumor effect Mouse (MC38) 213Bi 66
CTL ↑ Mouse (EL4) 90Y 82
T cell cytotoxic efficiency ↑ Cells (MC38, MDA-MB-231, ZR75-1, LNCaP, PC3, H1703, H441, OVCAR-3)/Mouse (MC38) 213Bi 223Ra 66, 72
Costimulatory molecules (ICOS and CTLA-4) ↑ Cells (MC38-CEA+)/Human (Prostate cancer) 223Ra 90Y 74, 81
Effector memory T cells ↑ Mouse (4T1, CT26) 131I 89
Th17 and Tc17 ↑ Human (Thyroid cancer) 131I 88
CTL/Treg ↑ Mouse (B78) 90Y 84
Treg ↓ Mouse (EL4) 90Y 82
Treg ↑ Human (Prostate cancer, thyroid cancer) 223Ra 131I 74, 88
Inhibitory molecules (PD-1) ↓ Human (Prostate cancer) 223Ra 73
inhibitory molecules (PD-1 and Tim-3) ↑ Mouse (MC38)/Human (Prostate cancer) 223Ra 177Lu 74, 94
Cytokine IFNγ, IFNβ, IL-17, IL-23, IL-10, TGF-β1, IL-6, CXCL-10↑ Mouse (B78, MOC2, 4T1, CT26)/Human (Thyroid cancer) 90Y 131I 83, 88, 89
Other immune cells DC, Innate myeloid, NK cells, and MDSC ↑ Mouse (MC38, B78)/Human (Prostate cancer) 213Bi 90Y 223Ra 66, 74, 84
Complement Complement C3 ↑ Mouse (A2058) 188Re 96
cGAS/STING cGAS/STING ↑ Mouse (B78) 90Y 84

MHC-1: Major histocompability complex-1; TAAs: Tumor-associated antigens; PSA: Prostate-specific antigen; CEA: Carcinoma embryonic antigen; MUC-1: mucin-1; CTL: cytotoxic T lymphocyte; DC: Dendritic cell; NK: Natural killer; MDSC: Myeloid-derived suppressor cell.